Cerus Corporation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cerus Corporation sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Cerus Corporation: 10 sponsored US clinical trials, 1 recruiting.

Cerus Corporation sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy Subjects, with 2 trials.

Top-decile sponsor footprint

Cerus Corporation ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1

NCT07015437
ACTIVE NOT RECRUITING Phase 3

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
NOT YET RECRUITING

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

NCT07218185
COMPLETED Phase 2

A Study to Assess Recovery and Survival of Radiolabeled Apheresis Platelet Components Treated With the INTERCEPT Blood System for Platelets With LED Illuminator.

NCT06697223
COMPLETED Phase 2

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

NCT04022889
COMPLETED Phase 3

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

NCT03459287
COMPLETED

A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components

NCT02549222
TERMINATED Phase 2

A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study

NCT02653443
TERMINATED Phase 1

A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease

NCT02295501
COMPLETED Phase 2

A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells

NCT01711346

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 5
Phase 3 2

Therapeutic Areas

Healthy Subjects 2
Anemia 1

What is open in the Cerus Corporation pipeline

1 recruiting of 10 indexed (10% open); 5 completed (50%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Healthy Subjects (2 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cerus Corporation: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Cerus Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Cerus CorporationAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Cerus Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cerus Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cerus Corporation page

10 registered trials is a research-attention snapshot, not an endorsement of Cerus Corporation or any single study.

  • 1 of Cerus Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy Subjects is the condition Cerus Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy Subjects trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cerus Corporation pipeline card: 10 registered trials from official public datasets.Report a data error.